Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03083821 | A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting | PHASE1 | COMPLETED | 6 | — | — | May 16, 2017 | Dec 19, 2017 | Nov 18, 2023 | 1 | Japan |
Cmax is defined as the peak plasma concentration
Tmax is defined as the time of maximum observed plasma concentration, measured in hours
Ctrough is defined as the trough in observed plasma (predose) concentrations
C24 is defined as the observed plasma concentration at 24 hours post-dose
AUC(TAU) is defined as the area under the concentration-time curve in one dosing interval
CLT/F is defined as the apparent total body clearance
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Baraclude | DRUG | Specified dose on specified day |
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. * Participants with chronic hepatitis B (CHB) (excluding participants with a superinfection) who have been confirmed to have CHB. * Participants who are being...